Precision Palliative Care for Patients With Advanced Esophageal Cancer: a Randomized Phase III Trial
The goal of this clinical trial is to learn if precision palliative care improves survival of patients with advanced esophageal cancer in adults. Researchers will compare precision palliative care and standard palliative care to see if precision palliative care works more effectively to treat advanced esophageal s cancer. Participants will receive precision palliative care or standard palliative care. All participants will answer survey questions about their quality of life, MDASI, PHQ-9, GAD-7 for 1 years.
• Written informed consent
• Aged ≥18 years
• Histologically confirmed esophageal cancer
• Clinical stages IV based on the 8th AJCC TNM classification, or recurrent esophageal cancer
• plan to treated with anti-PD-1/PD-L1 immunotherapy
• Eastern Cooperative Oncology Group(ECOG) performance status: 0-2
• Adequate organ functions Absolute neutrophil counts (ANC) ≥1.5×109⁄L; Hemoglobin (Hb) ≥9g⁄dl; Platelet (Plt) ≥100×109⁄L; Total bilirubin ≤1.5 upper limit of normal (ULN); Aspartate transaminase (AST) ≤2.5 ULN; Alanine aminotransferase (ALT) ≤2.5 ULN; Creatinine ≤1.5 ULN.